CL-316243

What it is

CL-316243 is a research compound developed as a selective beta-3 adrenergic receptor agonist. Beta-3 signaling in adipose tissue can increase lipolysis, fuel oxidation, and thermogenic activity. The strong body-fat and glucose effects commonly associated with the compound come mainly from rodent experiments, where beta-3 biology and drug response do not translate cleanly to people.

The limited human result

The direct human evidence is one small 1998 trial in 14 healthy, lean young men: ten received CL-316243 and four received placebo for eight weeks. At week eight, the treated group had greater 24-hour fat oxidation and lower carbohydrate oxidation, but no change in 24-hour energy expenditure, body weight, or body composition. That supports metabolic activity, not demonstrated fat loss.

The apparent slowdown

In that trial, insulin-mediated glucose disposal improved at week four, then the effect weakened by week eight as measured plasma CL-316243 concentrations unexpectedly declined. That makes a front-loaded response biologically interesting, but it does not prove receptor tolerance or explain my first-two-weeks observation. I did not measure drug exposure, insulin action, or substrate oxidation.

Why pre-workout feel was a weak measure

The published human experiment evaluated chronic metabolic effects, not a workout-timed performance intervention. It found no change in heart rate or blood pressure and no tremor, but the sample was far too small to establish broad safety. There is no direct human evidence validating 45-minute pre-workout timing or showing that a perceptible stimulant effect should occur.

Dose and formulation context

The old human trial used a very different daily regimen from this experiment. Without comparable route, formulation, pharmacokinetics, and exposure data, its dose does not convert into a practical comparison with mine. The published regimen is useful research context, not a dose match for this experiment.

Sources

• Weyer et al., Diabetes 1998 — eight-week randomized human trial measuring insulin action, energy metabolism, fat oxidation, and body composition.
• de Souza et al., Diabetes 1997 — rodent beta-3 agonism, glucose disposal, and adipose-tissue effects that helped establish the preclinical rationale.
• Jost et al., Experimental and Clinical Endocrinology & Diabetes 2005 — beta-3 signaling and glucose uptake in primary human adipocytes.

Protocol

I used 5 mg/day for approximately one month, timed about 45 minutes before training. This records what I did; it is not a suggested dose, timing strategy, or protocol.

Question

The practical question was whether CL-316243 would produce a noticeable fat-loss or body-composition signal within my existing diet and training routine, and whether there would be any acute effect around the workout.

Result

I did not feel an acute effect. The result was visual: I saw a clear reduction in body fat in the mirror, with most of the change occurring during the first two weeks before slowing down. CL-316243 worked quietly; the outcome showed up in appearance rather than in how I felt during training.

Interpretation

The practical endpoint was whether I saw a meaningful body-composition change in my routine. I did. The human literature makes increased fat oxidation plausible, while the decline in measured exposure during the human trial gives the slowdown some useful context. I am recording the slowdown as an observation rather than assigning it to a specific tolerance mechanism.

Decision

I am closing the run as helpful and removing CL-316243 from the active stack. It produced enough visible fat loss to count as a successful personal experiment. I am stopping now so I can evaluate SANA (MVD1) separately rather than overlapping the two experiments.